For instance, the administration of HLA-A2/3-restricted HER2 peptide (369–377) plus GM-CSF to patients with HER2-positive breast cancer following the completion of standard courses of therapy showed a 98.7% 5-year disease-free survival rate compared with an 80.2% rate for control patients (p = 0.08) [12], suggesting that the vaccine regimen might have some modest effect in preventing disease recurrence. The gene discussed is ERBB2; the disease is breast cancer.